The Center for Biosimilars® recaps the top news for the week of December 3, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 3.
Number 5: A new study found that CT-P10, a rituximab biosimilar, demonstrated comparable progression-free survival, sustained response, and overall survival with the reference product in patients with previously untreated advanced follicular lymphoma.
Number 4: The American College of Rheumatology and the National Psoriasis Foundation released a new treatment guideline for psoriatic arthritis that contains evidence-based recommendations on caring for patients with this inflammatory disease.
Number 3: A recent study found that using only tbo-filgrastim in treating neutropenia for patients undergoing cytotoxic chemotherapy in the Veterans Health Administration led to cost savings.
Number 2: A study presented at the American Society of Hematology’s annual meeting found that subcutaneously administered rituximab has the potential to save both cost and time.
Number 1: Celltrion has announced that the European Medicines Agency has accepted for review an extension marketing authorization application for a subcutaneous formulation of the company’s biosimilar infliximab, CT-P13.
Finally, last week, our e-newsletter asked if the FDA’s efforts to increase competition are enough to curb rising drug prices.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.